We are live on ! Find out more

Syndax Pharmaceuticals

SNDX

Market cap $1.6B

17.92 USD

-0.43

2.34%

At close Updated Sep 15, 1:50 PM EDT

1 day

-2.34%

5 days

-9.59%

1 month

-9.31%

3 months

-3.03%

6 months

-25.46%

Year to date

-15.87%

1 year

13.13%

5 years

-7.44%

10 years

20.35%

About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Employees: 298

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.3%

Neutral 58.8%

Negative 5.9%

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in September Investor Conferences

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.

Syndax Announces Participation in September Investor Conferences

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Zacks Investment Research

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

See News Rankings

Price charts implemented using Lightweight Charts™